| 000 | 031430000a22008050004500 | ||
|---|---|---|---|
| 001 | 000655 | ||
| 005 | 20230526120517.0 | ||
| 046 | _j20010000 | ||
| 245 | _aThe use of antimalarial drugs: report of a WHO informal consultation | ||
| 260 | _bWHO | ||
| 260 | _c2001 | ||
| 270 | _bGeneva | ||
| 270 | _dCH | ||
| 300 | _a141 p. | ||
| 300 | _bdiagrs., tabls., ilus. | ||
| 505 | _aPolicy implications: | ||
| 505 | _aCurrent status of antimalarial drug resistance: | ||
| 505 | _adevelopment of resistance. | ||
| 505 | _aAssessment of antimalarial drug susceptibility. | ||
| 505 | _aPlasmodium falciparum resistance. | ||
| 505 | _aPlasmodium vivax resistance. | ||
| 505 | _aCombination Therapy: | ||
| 505 | _aRationale for the use of combination therapy. | ||
| 505 | _aArtemisinin - based combination therapy. | ||
| 505 | _aImplementation of combination therapy - operational isues. | ||
| 505 | _aChemoprophylaxis and treatment of malaria in special groups: | ||
| 505 | _aChemoprophylaxis and intermittent treatment of malaria in pregnancy. | ||
| 505 | _aChemoprophylaxis and stand-by treatment in travellers. | ||
| 505 | _aManagement of severe malaria. | ||
| 505 | _aVivax malaria. | ||
| 505 | _aFormulations for paediatric use. | ||
| 505 | _aAntimalarial treatment policies: | ||
| 505 | _aDefinition. | ||
| 505 | _aPurpose. | ||
| 505 | _aDevelopment. | ||
| 505 | _aFactors influencing antimalarial treatment policies. | ||
| 505 | _aHealth-seeking behavior | ||
| 505 | _aCriteria for changing treatment poicy | ||
| 505 | _aProcess of changing treatment policy - country examples | ||
| 505 | _aImplementation and access to antimalarial drugs in endemic countries | ||
| 505 | _aAntimalarial drugs for malaria prevention and treatment | ||
| 505 | _aChloroquince | ||
| 505 | _aAmodiaquine | ||
| 505 | _aAntifolate drugs sulfa drug - pyrimethamine combinations | ||
| 505 | _aProguanil. | ||
| 505 | _aMefloquine | ||
| 505 | _aQuinine, quinidine and related alkaloids | ||
| 505 | _aHalofantrine | ||
| 505 | _aArtemisinin and its derivatives | ||
| 505 | _aPrimaquine | ||
| 505 | _aAntibiotics used as antimalarial drugs | ||
| 505 | _aAtovaquone-proguanil | ||
| 505 | _aChloroquine-proguanil | ||
| 505 | _aArtemether - lumefantrine | ||
| 505 | _aMefloquine-sulfadoxine - pyrimethamine | ||
| 505 | _aStatus and potential of combination therapies | ||
| 505 | _aPast or present co-administered non fixed combinations | ||
| 505 | _aCombinations undergoing consideration or trial | ||
| 505 | _aPotential combinations under consideration or trial with not yet available drugs | ||
| 505 | _aGuidance on the selection of drugs for national antimalarial treatment policies | ||
| 505 | _aCommon antimalarial drugs that should be considered in drug selection | ||
| 546 | _aInglés | ||
| 650 | _aMALARIA | ||
| 650 | _aPALUDISMO/quimioterapia | ||
| 650 | _aANTIMALÁRICOS | ||
| 650 | _xEpidemiología de Enfermedades Metaxénicas y Saneamiento Ambiental | ||
| 710 | _aOrganización Mundial de la Salud. Roll Back Malaria | ||
| 852 |
_aQV256 _bW67 _c2001 |
||
| 942 | _cLB | ||
| 999 |
_c3379 _d3379 |
||